Gastroenterology
Volume 136, Issue 2 , Pages 389-392 , February 2009

Hepatitis B: A “GLOBAL” Health Challenge

  • Robert J. Fontana

      Affiliations

    • Corresponding Author InformationAddress requests for reprints to: Robert J. Fontana, MD, Associate Professor of Medicine, 3912 Taubman Center, Ann Arbor, MI 48109-0362. fax: 734-936-7392

References 

  1. Centers for Disease Control and Prevention. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. 2006;55:1–41
  2. Centers for Disease Control and Prevention. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR. 2008;57:1–16
  3. Kim WR, Ishitani MB, Dickson ER. Rising burden of hepatitis B in the United States: Should the ‘other’ virus be forgotten?. Hepatology. 2002;36:222A;(Abstract)
  4. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996;334:1422–1427
  5. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351:1521–1531
  6. National Institutes of Health. Consensus Development Conference statement, management of hepatitis B. October 20–22, 2008 http://www.natap.org/2008/HBV/102308_01.htmAccessed November 5, 2008
  7. Keeffe EB, Dieterich KT, Han SHB, et al. A treatment algorithm for the Management of Chronic Hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6:1315–1341
  8. Lok ASF, McMahon BJ. AASLD practice guideline: chronic hepatitis B. Hepatology. 2007;45:507–539
  9. Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124:105–117
  10. Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology. 2007;132:1574–1585
  11. Liaw YF, Gane E, Leung N, et al. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2008;136:486–495
  12. Chan HLY, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e-antigen positive chronic hepatitis with telbivudine or adefovir. Ann Intern Med. 2007;147:745–754
  13. Han SH, Chang TT, Chao YC, et al. Five years of continuous entecavir for nucleoside-naïve HBeAg (+) chronic hepatitis B: results from study ETV 901. Hepatology. 2008;48(4 Suppl 1):705A;(abstract)
  14. Snow-Lampart A, Chappell BJ, Curtis M, et al. Week 96 resistance surveillance for HBeAg positive and negative subjects with chronic HBV infection randomized to receive Tenofovir DF 300 mg q d. Hepatology. 2008;48(4 Suppl 1):197A;(abstract)
  15. Van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology. 2004;40:1421–1425
  16. Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir for the treatment of HBeAg positive chronic hepatitis B. J Hepatol. 2008;48:728–735
  17. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005;129:528–536
  18. Antiretroviral Pregnancy Registry. www.apregistry.comAccessed October 1, 2008
  19. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral treatment of adult HIV infection. JAMA. 2008;300:555–570

 The author discloses the following: Dr Fontana has been a consultant or on the Speaker's Bureau for Roche Laboratories, Bristol-Meyers-Squibb, Gilead Sciences, and GlaxoSmithKline.

PII: S0016-5085(08)02195-1

doi: 10.1053/j.gastro.2008.12.018

Gastroenterology
Volume 136, Issue 2 , Pages 389-392 , February 2009

Article Tools